Search results
NurExone’s ExoPTEN Being Studied as Glaucoma Treatment for US$3.4 Billion Market
Digital Journal· 4 days agoNurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, is pleased to announce a pre-clinical study to explore ...